all investments current investments previous investments


Bind Therapeutics (BIND) is a biopharmaceutical company developing therapeutic targeted nanoparticles.


Medical Technology company developing a device to improve the care of type 2 diabetic patients.


Chrono is building a next generation transdermal drug delivery wearable that integrates biologically-timed drug delivery with personalised digital support. First application is nicotine replacement therapy for the smoking cessation market.


EndoStim has developed an implantable neuromodulation system for the treatment of severe gastro esophageal reflux disease (GERD).


Gynesonics designs and develops new and advanced technologies for improving women’s health. The company is focused on providing to women, and the physicians who care for them, an incision-free, uterus-preserving option to treat symptomatic uterine fibroids. The Sonata™ system combines intrauterine sonography with radio-frequency ablation to precisely locate and ablate uterine fibroids associated with heavy menstrual symptoms in a simple, same-day procedure. The system is cleared for sale in Europe (CE Mark) and the company is currently enrolling its US pivotal trial to evaluate safety and effectiveness. Sonata offers the potential to reduce the number of more invasive procedures, including hysterectomy, and to offer women greater choices in the treatment of this very common condition.


Biomaterials and bioactives for chronic wounds and bone regeneration.


Molecular Partners is developing a novel class of binding proteins (DARPins) that will compete with monoclonal antibodies by addressing some of their weaknesses.


Drug develpment company focused on the new therapies for immune-related disorders and inflammation.




Sophia Genetics is a pioneer in Data-Driven Medicine, a crossover field that requires deep expertise in Next Generation Sequencing (NGS), combined with highly accurate and scalable predictive algorithms to diagnose genetic diseases.


Symetis has developed a minimally invasive Transcatheter Aortic Valve Implantation (TAVI) system to treat patients suffering from aortic valve stenosis.
    


Indication for pulmonary arterial hypertension (PAH), a life-threatening disorder which severely compromises the function of the lungs and heart. IPO on SWX in April 2000.


Founded in April 2000. Discovery and development of small molecules active on novel G protein-coupled receptors. CHF38 Mio raised, 60 employees. Most advanced project (Phase II): sub-arachnoid haemorrhage. Acquired by Actelion (ATLN) in October 2003.


Medical technology company with a device to treat morbid obese patients. A gastric band restricts food intake, and is remotely controlled by the medical doctor. Company sold to Allergan (AGN) in February 2007.


Discovery and development of SGDs (small glycan drugs) to provide the patient with safer and more efficient anti-thrombotics.


Flamentera is developing monitoring tests for celiac disease


Fully automated system for molecular biology diagnostics enabling easy DNA extraction and fast detection of bacteria.


Lumavita is a biotech-pharma company based in Basel, Switzerland, specialising in Woman’s Health.


Neocutis is a spin-off from the CHUV hospital in Lausanne, focused on innovative dermatology, skin care, wound healing treatment and cosmetics.


Developing next generation treatment for brain aneurysms. Covidien acquired Nfocus Neuromedical in February 2013.


Mid-stage specialty pharmaceutical company in dental market. The Novalar product (a vasodilatator), rapidly reverses the lingering and debilitating lip and tongue numbness associated with local dental anesthesia.


OncoEthix is a drug development company dedicated to the development of compounds in oncology.


Indications of stroke and the related indications neuronal damage and thrombotic disease. IPO on Frankfurt exchange (PA8) in February 2005.


PneumRx is developing and marketing minimally invasive therapeutic devices to treat emphysema patients.


Develop, manufacture, and market dental implant systems. Sold participation in January 2006.
 


Indication for pulmonary arterial hypertension (PAH), a life-threatening disorder which severely compromises the function of the lungs and heart. IPO on SWX in April 2000.


Founded in April 2000. Discovery and development of small molecules active on novel G protein-coupled receptors. CHF38 Mio raised, 60 employees. Most advanced project (Phase II): sub-arachnoid haemorrhage. Acquired by Actelion (ATLN) in October 2003.


Bind Therapeutics (BIND) is a biopharmaceutical company developing therapeutic targeted nanoparticles.


Medical Technology company developing a device to improve the care of type 2 diabetic patients.


Chrono is building a next generation transdermal drug delivery wearable that integrates biologically-timed drug delivery with personalised digital support. First application is nicotine replacement therapy for the smoking cessation market.


Medical technology company with a device to treat morbid obese patients. A gastric band restricts food intake, and is remotely controlled by the medical doctor. Company sold to Allergan (AGN) in February 2007.


EndoStim has developed an implantable neuromodulation system for the treatment of severe gastro esophageal reflux disease (GERD).


Discovery and development of SGDs (small glycan drugs) to provide the patient with safer and more efficient anti-thrombotics.


Flamentera is developing monitoring tests for celiac disease


Fully automated system for molecular biology diagnostics enabling easy DNA extraction and fast detection of bacteria.


Gynesonics designs and develops new and advanced technologies for improving women’s health. The company is focused on providing to women, and the physicians who care for them, an incision-free, uterus-preserving option to treat symptomatic uterine fibroids. The Sonata™ system combines intrauterine sonography with radio-frequency ablation to precisely locate and ablate uterine fibroids associated with heavy menstrual symptoms in a simple, same-day procedure. The system is cleared for sale in Europe (CE Mark) and the company is currently enrolling its US pivotal trial to evaluate safety and effectiveness. Sonata offers the potential to reduce the number of more invasive procedures, including hysterectomy, and to offer women greater choices in the treatment of this very common condition.


Biomaterials and bioactives for chronic wounds and bone regeneration.


Lumavita is a biotech-pharma company based in Basel, Switzerland, specialising in Woman’s Health.


Molecular Partners is developing a novel class of binding proteins (DARPins) that will compete with monoclonal antibodies by addressing some of their weaknesses.


Neocutis is a spin-off from the CHUV hospital in Lausanne, focused on innovative dermatology, skin care, wound healing treatment and cosmetics.


Developing next generation treatment for brain aneurysms. Covidien acquired Nfocus Neuromedical in February 2013.


Mid-stage specialty pharmaceutical company in dental market. The Novalar product (a vasodilatator), rapidly reverses the lingering and debilitating lip and tongue numbness associated with local dental anesthesia.


Drug develpment company focused on the new therapies for immune-related disorders and inflammation.


OncoEthix is a drug development company dedicated to the development of compounds in oncology.


Indications of stroke and the related indications neuronal damage and thrombotic disease. IPO on Frankfurt exchange (PA8) in February 2005.


PneumRx is developing and marketing minimally invasive therapeutic devices to treat emphysema patients.




Sophia Genetics is a pioneer in Data-Driven Medicine, a crossover field that requires deep expertise in Next Generation Sequencing (NGS), combined with highly accurate and scalable predictive algorithms to diagnose genetic diseases.


Symetis has developed a minimally invasive Transcatheter Aortic Valve Implantation (TAVI) system to treat patients suffering from aortic valve stenosis.


Develop, manufacture, and market dental implant systems. Sold participation in January 2006.
© Endeavour Vision SA 2006-2017 Terms & Conditions